Pla2 polymorphism of β3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular Injury

Circulation

Volumn 104, Issue 22, 2001, Pages 2666-2672

  Undas, Anetta ^a   Brummel, Kathleen ^b   Musial, Jacek ^a   Mann, Kenneth G ^b   Szczeklik, Andrew ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Aspirin; Coagulation; Genetics; Glycoproteins; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; GLYCOPROTEIN; PHOSPHOLIPASE A2; PROTHROMBIN; THROMBIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD VESSEL INJURY; CORONARY RISK; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENETIC POLYMORPHISM; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL;

EID: 0035960620     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4701.099787     Document Type: Article

References (34)

1. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein IIb/IIIa complex
2. Glycoprotein IIb/IIIa inhibitors: Current indications and future prospects
3. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds
4. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia
5. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing
6. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young Central Europeans
7. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
8. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death
9. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction
10. A2 polymorphism: The Framingham Off-spring Study
11. A2 polymorphism
12. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
13. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease
14. A2 alloantigen on the function of integrins in platelets
15. Platelet glycoprotein IIIa polymorphism and coronary thrombosis
16. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation
17. Relationship between bleeding time, aspirin, and the PlA1/A2 polymorphism of platelet glycoprotein IIIa
18. A2 polymorphism and efficacy of aspirin
19. Antiplatelet drugs and generation of thrombin in clotting blood
20. Blood clotting in minimally altered whole blood
21. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation
22. An integrated study of fibrinogen during blood coagulation
23. 3 Blood
24. 3 enhances outside-in signaling and adhesive functions
25. The coagulation explosion
26. Studies of thromboxane B2, platelet factor 4 and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage defects
27. Networking in the hemostatic system. Integrin αIIb33 binds prothrombin and influences its activation
28. Vβ3 on vascular cells controls recognition of prothrombin
29. Measurement of thrombin generation in whole blood - The effect of heparin and aspirin
30. Coagulation, fibrinolytic and platelet function in patients in long-term therapy with 300 mg or 1200 mg daily compared with placebo
31. Platelet glycoprotein IIIa PlA polymorphism and effects of aspirin on thrombin generation
32. 3 activation by non-steroidal antiinflammatory drugs
33. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin
34. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatydylserine expression in whole blood